Navigation Links
New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Date:12/13/2007

Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for

In-Person Workshops

MALVERN, Pa., Dec. 13 /PRNewswire/ -- In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) University, an online, self-study resource that incorporates new learning technology. The course integrates multi-dimensional, life-like animation throughout the content -- with anatomy based on real patients with CD and actual injection technique demonstrations with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution. The course can be accessed at http://www.myoblocuniversity.com.

"MYOBLOC(TM) University is for busy physician specialists who want to expand the scope of treatment options for their patients with cervical dystonia, and for those seeking a comprehensive review of the condition and the role of botulinum toxin type B," said Eric J. Pappert, MD, assistant professor of neurology and director of the Parkinson's Disease and Movement Disorders Program at the University of Texas Health Science Center in San Antonio, Texas and Vice President, Medical & Scientific Affairs of Solstice. Dr. Pappert led the development of MYOBLOC(TM) University.

CD is often a disabling and painful movement disorder that requires life- long management. Also known as spasmodic torticollis, it is a condition that primarily affects the cervical area of the neck. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. The treatment goal is to lessen symptoms of spasms, pain and impaired posture, and to improve functionality.

"A broad range of treatment options are often needed to address the symptoms of cervical dystonia. The botulinum toxins are considered the primary and most effective form of treatment, which makes it critically important for physicians to be experienced with both forms of botulinum toxin available here in the U.S.," noted Dr. Pappert.
The multi-media content covered in MYOBLOC(TM) University includes:

-- Detailed overview of the clinical presentation and diagnosis of CD --

with video depictions demonstrating abnormal movements and which muscle

are involved

-- Review of currently available treatments -- oral medications, surgical

options, injections with botulinum toxin, and complementary therapies

-- Fundamentals for dosing and muscle injection techniques when using

MYOBLOC to reduce the severity of abnormal head position and neck pain

associated with CD

-- Patient case studies that illustrate the challenges and potential

solutions in managing CD patients

-- A post-test for participants to gauge their understanding of the

materials presented

Upon completing the online lesson, physicians can request in-person training with MYOBLOC, which is available through Solstice in a variety of venues. The company's overall goal is to support physicians who care for CD patients -- ranging from neurologists to physiatrists to anesthesiologists and pain management physicians.

MYOBLOC(TM) University does not offer continuing medical education credits.

About MYOBLOC

Myobloc(R) (Botulinum Toxin Type B) Injectable Solution is indicated for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Before administering MYOBLOC, physicians should consult the full Prescribing Information.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. These adverse events are generally mild to moderate, transient, self-resolving, and more common with higher doses.

For full Prescribing Information, please visit http://www.myobloc.com.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.

Editor's Note: for access to current course offerings, users must register on website; users can access site regardless of medical credentials.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Social Network for Scientists Marks Ten Years Online
2. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
3. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
4. Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs
5. New Online Help Desk Offers Safe Lifting Assistance to Healthcare Facilities
6. MIT: Leveraging learning for artificial respiration
7. MIT: Leveraging learning for artificial respiration
8. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
9. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
10. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
11. New designer toxins kill Bt-resistant insect pests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2017)... ... September 15, 2017 , ... San Diego based ... ‘Internal Seed B’ round of financing, totaling $600,000. The round was entirely ... ‘SAFE’ documentation structure at a company valuation of $10M. , Grolltex, ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... (CC) product portfolio, clinically-relevant starting and ancillary materials that generate unprecedented efficiencies ... Cell (hMSC)-based therapies. The CliniControl product portfolio will radically simplify major steps ...
(Date:9/14/2017)... ... September 14, 2017 , ... One of the world’s largest World ... , For six hours that day, the GenCure Marrow Donor Program will be signing ... H-E-B grocery stores in San Antonio. , The registration tables will be staffed by ...
(Date:9/13/2017)... ... September 13, 2017 , ... ... life sciences industry to improve patient outcomes and quality of life for more ... has been named a US expert to the International Standards Organization/Technical Committee ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):